Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTG21IS)

• DTT Name: HUMAN basigin (BSG)
• Synonyms: UNQ6505/PRO21383; Tumor cell-derived collagenase stimulatory factor; TCSF; OK blood group antigen; Leukocyte activation antigen M6; Extracellular matrix metalloproteinase inducer; EMMPRIN; 5F7
• Gene Name: BSG
• BioChemical Class: Basigin protein
• UniProt ID: BASI_HUMAN
• TTD ID: T94933
• Sequence:
  MAAALFVLLGFALLGTHGASGAAGFVQAPLSQQRWVGGSVELHCEAVGSPVPEIQWWFEG
  QGPNDTCSQLWDGARLDRVHIHATYHQHAASTISIDTLVEEDTGTYECRASNDPDRNHLT
  RAPRVKWVRAQAVVLVLEPGTVFTTVEDLGSKILLTCSLNDSATEVTGHRWLKGGVVLKE
  DALPGQKTEFKVDSDDQWGEYSCVFLPEPMGTANIQLHGPPRVKAVKSSEHINEGETAML
  VCKSESVPPVTDWAWYKITDSEDKALMNGSESRFFVSSSQGRSELHIENLNMEADPGQYR
  CNGTSSKGSDQAIITLRVRSHLAALWPFLGIVAEVLVLVTIIFIYEKRRKPEDVLDDDDA
  GSAPLKSSGQHQNDKGKNVRQRNSS
• Function: Plays pivotal roles in spermatogenesis, embryo implantation, neural network formation and tumor progression. Stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPS). Seems to be a receptor for oligomannosidic glycans. In vitro, promotes outgrowth of astrocytic processes. Plays an important role in targeting the monocarboxylate transporters SLC16A1, SLC16A3, SLC16A8, SLC16A11 and SLC16A12 to the plasma membrane.
• Reactome Pathway:
  Basigin interactions (R-HSA-210991)
  Integrin cell surface interactions (R-HSA-216083)
  Proton-coupled monocarboxylate transport (R-HSA-433692)
  Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) (R-HSA-5619070)
  Pyruvate metabolism (R-HSA-70268)
  Aspirin ADME (R-HSA-9749641)
  Degradation of the extracellular matrix (R-HSA-1474228)

Molecular Interaction Atlas (MIA) of This DTT

1 Drugs in Phase 1 Trial Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meplazumab	DMJVFK7	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1/2 Trial	[1]

References

• [1] Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial